Sana Biotechnology Q1 FY26 net loss narrows to $47.2 million

• Sana Biotechnology posted a Q1 net loss of $47.2 million, or $0.17 per share, narrowing from $49.4 million, or $0.21 per share, a year earlier.
• Research and development expense fell 22.85% to $28.7 million, while general and administrative expense was flat at $11.5 million.
• Cash, cash equivalents, and marketable securities dropped to $101.1 million, down from $138.4 million at year-end, while non-GAAP operating cash burn improved to $37.0 million from $46.6 million a year earlier.
• Mayo Clinic agreed to invest about $25 million in an equity stake as part of a strategic collaboration to advance SC451, with an option for an additional roughly $25 million investment.
• Sana reiterated plans to file an IND and start a Phase 1 trial for SC451 later this year, reported positive 14-month results from an investigator-sponsored UP421 transplant without immunosuppression, and kept SG293 on track for clinical testing later this year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sana Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605111605PRIMZONEFULLFEED9717667) on May 11, 2026, and is solely responsible for the information contained therein.